2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Buy
59
RGLS Quote, Financials, Valuation and Earnings
Last price:
$7.94
Seasonality move
:
-22.76%
Day range:
$7.91 - $7.95
52-week range:
$0.83 - $8.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
7.95x
Volume:
1M
Avg. volume:
2.4M
1-year change:
250.89%
Market cap:
$549M
Revenue:
--
EPS (TTM):
-$0.73
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RGLS
Regulus Therapeutics
|
-- | -$0.27 | -- | -5.88% | $8.80 |
|
A
Agilent Technologies
|
$1.6B | $1.26 | 5.43% | 40.52% | $137.60 |
|
BCDA
BioCardia
|
-- | -$0.87 | -100% | -36.96% | $6.00 |
|
CRMD
Cormedix
|
$36M | $0.25 | 3606.46% | -38.24% | $16.83 |
|
PFE
Pfizer
|
$14.1B | $0.67 | 1.07% | 5523.4% | $29.24 |
|
SWTX
SpringWorks Therapeutics
|
$67M | -$0.81 | 22.87% | -79.63% | $47.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RGLS
Regulus Therapeutics
|
$7.93 | $8.80 | $549M | -- | $0.00 | 0% | -- |
|
A
Agilent Technologies
|
$111.92 | $137.60 | $31.8B | 27.63x | $0.25 | 0.87% | 4.85x |
|
BCDA
BioCardia
|
$2.16 | $6.00 | $11.2M | -- | $0.00 | 0% | 17.59x |
|
CRMD
Cormedix
|
$12.14 | $16.83 | $823.4M | 55.18x | $0.00 | 0% | 9.08x |
|
PFE
Pfizer
|
$23.49 | $29.24 | $133.5B | 17.02x | $0.43 | 7.24% | 2.14x |
|
SWTX
SpringWorks Therapeutics
|
$46.71 | $47.00 | $3.5B | -- | $0.00 | 0% | 15.82x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RGLS
Regulus Therapeutics
|
-- | -7.910 | -- | -- |
|
A
Agilent Technologies
|
36.29% | 1.468 | 11.44% | 1.42x |
|
BCDA
BioCardia
|
-- | -2.199 | -- | 0.35x |
|
CRMD
Cormedix
|
-- | 2.314 | -- | 3.84x |
|
PFE
Pfizer
|
40.42% | 0.423 | 42.46% | 0.88x |
|
SWTX
SpringWorks Therapeutics
|
-- | 1.640 | -- | 3.99x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RGLS
Regulus Therapeutics
|
-- | -$10.5M | -- | -- | -- | -$10.6M |
|
A
Agilent Technologies
|
$866M | $300M | 12.7% | 19.32% | 17.33% | $107M |
|
BCDA
BioCardia
|
-- | -$2.7M | -938.6% | -938.6% | -54966.67% | -$1.6M |
|
CRMD
Cormedix
|
$37.5M | $20.1M | 23.7% | 23.7% | 52.85% | $19.7M |
|
PFE
Pfizer
|
$10.9B | $4.4B | 5.05% | 8.72% | 25.08% | $1.8B |
|
SWTX
SpringWorks Therapeutics
|
$45.6M | -$80.5M | -49.69% | -49.69% | -167.44% | -$68.8M |
Regulus Therapeutics vs. Competitors
-
Which has Higher Returns RGLS or A?
Agilent Technologies has a net margin of -- compared to Regulus Therapeutics's net margin of 12.89%. Regulus Therapeutics's return on equity of -- beat Agilent Technologies's return on equity of 19.32%.
Company Gross Margin Earnings Per Share Invested Capital RGLSRegulus Therapeutics-- -$0.15 -- AAgilent Technologies51.92% $0.75 $9.6B -
What do Analysts Say About RGLS or A?
Regulus Therapeutics has a consensus price target of $8.80, signalling upside risk potential of 10.97%. On the other hand Agilent Technologies has an analysts' consensus of $137.60 which suggests that it could grow by 22.95%. Given that Agilent Technologies has higher upside potential than Regulus Therapeutics, analysts believe Agilent Technologies is more attractive than Regulus Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings RGLSRegulus Therapeutics1 4 0 AAgilent Technologies8 9 0 -
Is RGLS or A More Risky?
Regulus Therapeutics has a beta of 0.494, which suggesting that the stock is 50.604% less volatile than S&P 500. In comparison Agilent Technologies has a beta of 1.267, suggesting its more volatile than the S&P 500 by 26.695%.
-
Which is a Better Dividend Stock RGLS or A?
Regulus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agilent Technologies offers a yield of 0.87% to investors and pays a quarterly dividend of $0.25 per share. Regulus Therapeutics pays -- of its earnings as a dividend. Agilent Technologies pays out 21.26% of its earnings as a dividend. Agilent Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RGLS or A?
Regulus Therapeutics quarterly revenues are --, which are smaller than Agilent Technologies quarterly revenues of $1.7B. Regulus Therapeutics's net income of -$9.6M is lower than Agilent Technologies's net income of $215M. Notably, Regulus Therapeutics's price-to-earnings ratio is -- while Agilent Technologies's PE ratio is 27.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regulus Therapeutics is -- versus 4.85x for Agilent Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGLSRegulus Therapeutics-- -- -- -$9.6M AAgilent Technologies4.85x 27.63x $1.7B $215M
-
Which has Higher Returns RGLS or BCDA?
BioCardia has a net margin of -- compared to Regulus Therapeutics's net margin of -54866.67%. Regulus Therapeutics's return on equity of -- beat BioCardia's return on equity of -938.6%.
Company Gross Margin Earnings Per Share Invested Capital RGLSRegulus Therapeutics-- -$0.15 -- BCDABioCardia-- -$0.59 -$2M -
What do Analysts Say About RGLS or BCDA?
Regulus Therapeutics has a consensus price target of $8.80, signalling upside risk potential of 10.97%. On the other hand BioCardia has an analysts' consensus of $6.00 which suggests that it could grow by 177.78%. Given that BioCardia has higher upside potential than Regulus Therapeutics, analysts believe BioCardia is more attractive than Regulus Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings RGLSRegulus Therapeutics1 4 0 BCDABioCardia1 0 0 -
Is RGLS or BCDA More Risky?
Regulus Therapeutics has a beta of 0.494, which suggesting that the stock is 50.604% less volatile than S&P 500. In comparison BioCardia has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.738%.
-
Which is a Better Dividend Stock RGLS or BCDA?
Regulus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioCardia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regulus Therapeutics pays -- of its earnings as a dividend. BioCardia pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RGLS or BCDA?
Regulus Therapeutics quarterly revenues are --, which are smaller than BioCardia quarterly revenues of $3K. Regulus Therapeutics's net income of -$9.6M is lower than BioCardia's net income of -$2.7M. Notably, Regulus Therapeutics's price-to-earnings ratio is -- while BioCardia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regulus Therapeutics is -- versus 17.59x for BioCardia. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGLSRegulus Therapeutics-- -- -- -$9.6M BCDABioCardia17.59x -- $3K -$2.7M
-
Which has Higher Returns RGLS or CRMD?
Cormedix has a net margin of -- compared to Regulus Therapeutics's net margin of 52.82%. Regulus Therapeutics's return on equity of -- beat Cormedix's return on equity of 23.7%.
Company Gross Margin Earnings Per Share Invested Capital RGLSRegulus Therapeutics-- -$0.15 -- CRMDCormedix95.91% $0.30 $114.9M -
What do Analysts Say About RGLS or CRMD?
Regulus Therapeutics has a consensus price target of $8.80, signalling upside risk potential of 10.97%. On the other hand Cormedix has an analysts' consensus of $16.83 which suggests that it could grow by 38.66%. Given that Cormedix has higher upside potential than Regulus Therapeutics, analysts believe Cormedix is more attractive than Regulus Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings RGLSRegulus Therapeutics1 4 0 CRMDCormedix3 0 0 -
Is RGLS or CRMD More Risky?
Regulus Therapeutics has a beta of 0.494, which suggesting that the stock is 50.604% less volatile than S&P 500. In comparison Cormedix has a beta of 1.538, suggesting its more volatile than the S&P 500 by 53.821%.
-
Which is a Better Dividend Stock RGLS or CRMD?
Regulus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cormedix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regulus Therapeutics pays -- of its earnings as a dividend. Cormedix pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RGLS or CRMD?
Regulus Therapeutics quarterly revenues are --, which are smaller than Cormedix quarterly revenues of $39.1M. Regulus Therapeutics's net income of -$9.6M is lower than Cormedix's net income of $20.6M. Notably, Regulus Therapeutics's price-to-earnings ratio is -- while Cormedix's PE ratio is 55.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regulus Therapeutics is -- versus 9.08x for Cormedix. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGLSRegulus Therapeutics-- -- -- -$9.6M CRMDCormedix9.08x 55.18x $39.1M $20.6M
-
Which has Higher Returns RGLS or PFE?
Pfizer has a net margin of -- compared to Regulus Therapeutics's net margin of 21.63%. Regulus Therapeutics's return on equity of -- beat Pfizer's return on equity of 8.72%.
Company Gross Margin Earnings Per Share Invested Capital RGLSRegulus Therapeutics-- -$0.15 -- PFEPfizer79.26% $0.52 $151.9B -
What do Analysts Say About RGLS or PFE?
Regulus Therapeutics has a consensus price target of $8.80, signalling upside risk potential of 10.97%. On the other hand Pfizer has an analysts' consensus of $29.24 which suggests that it could grow by 24.47%. Given that Pfizer has higher upside potential than Regulus Therapeutics, analysts believe Pfizer is more attractive than Regulus Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings RGLSRegulus Therapeutics1 4 0 PFEPfizer7 15 1 -
Is RGLS or PFE More Risky?
Regulus Therapeutics has a beta of 0.494, which suggesting that the stock is 50.604% less volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.
-
Which is a Better Dividend Stock RGLS or PFE?
Regulus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.24% to investors and pays a quarterly dividend of $0.43 per share. Regulus Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.
-
Which has Better Financial Ratios RGLS or PFE?
Regulus Therapeutics quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $13.7B. Regulus Therapeutics's net income of -$9.6M is lower than Pfizer's net income of $3B. Notably, Regulus Therapeutics's price-to-earnings ratio is -- while Pfizer's PE ratio is 17.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regulus Therapeutics is -- versus 2.14x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGLSRegulus Therapeutics-- -- -- -$9.6M PFEPfizer2.14x 17.02x $13.7B $3B
-
Which has Higher Returns RGLS or SWTX?
SpringWorks Therapeutics has a net margin of -- compared to Regulus Therapeutics's net margin of -169.47%. Regulus Therapeutics's return on equity of -- beat SpringWorks Therapeutics's return on equity of -49.69%.
Company Gross Margin Earnings Per Share Invested Capital RGLSRegulus Therapeutics-- -$0.15 -- SWTXSpringWorks Therapeutics92.82% -$1.11 $417.4M -
What do Analysts Say About RGLS or SWTX?
Regulus Therapeutics has a consensus price target of $8.80, signalling upside risk potential of 10.97%. On the other hand SpringWorks Therapeutics has an analysts' consensus of $47.00 which suggests that it could grow by 0.62%. Given that Regulus Therapeutics has higher upside potential than SpringWorks Therapeutics, analysts believe Regulus Therapeutics is more attractive than SpringWorks Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings RGLSRegulus Therapeutics1 4 0 SWTXSpringWorks Therapeutics0 6 0 -
Is RGLS or SWTX More Risky?
Regulus Therapeutics has a beta of 0.494, which suggesting that the stock is 50.604% less volatile than S&P 500. In comparison SpringWorks Therapeutics has a beta of 0.774, suggesting its less volatile than the S&P 500 by 22.596%.
-
Which is a Better Dividend Stock RGLS or SWTX?
Regulus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SpringWorks Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regulus Therapeutics pays -- of its earnings as a dividend. SpringWorks Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RGLS or SWTX?
Regulus Therapeutics quarterly revenues are --, which are smaller than SpringWorks Therapeutics quarterly revenues of $49.1M. Regulus Therapeutics's net income of -$9.6M is higher than SpringWorks Therapeutics's net income of -$83.2M. Notably, Regulus Therapeutics's price-to-earnings ratio is -- while SpringWorks Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regulus Therapeutics is -- versus 15.82x for SpringWorks Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGLSRegulus Therapeutics-- -- -- -$9.6M SWTXSpringWorks Therapeutics15.82x -- $49.1M -$83.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Asana Stock Be in 5 Years?
Asana stock hasn’t given many investors on Wall Street any…
Where Will Dell Stock Be in 5 Years?
So you’re looking at Dell (NASDAQ: DELL) and wondering, “Is…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for May 31
Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.
Buy
55
RGC alert for May 31
Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.
Sell
42
AMBA alert for May 31
Ambarella [AMBA] is down 15.13% over the past day.
